人眼晶体悬韧带的张力测定

目的:进行人眼晶体悬韧带部位及其张力的测定。　方法:对26只离体尸眼进行测定。悬韧带的最大张力规定为:在其放松及最大伸张情况下,从睫状突到嵌入晶体前囊膜内的悬韧带的距离的差值。　　结果:悬韧带在拉断之前平均能被拉长4.48±1.78mm,年轻组为5.33±1.19mm,老年组为2.17±0.70mm。无韧带区老年组为6.98±0.70mm,年轻组为7.66±0.42mm,平均为7.48±0.58mm。结论:悬韧带具有一定的张力,随着年龄的增长,悬韧带有向囊膜中心生长的趋势,无韧带区随年龄的增加而减小,悬韧带的张力随年龄的增加而减少。     

HLA genotyping of colorectal carcinoma in the Chinese population.

The HLA-DR genotypes of 61 primary colorectal carcinomas obtained from patients of Chinese origin were determined by using DNA-RFLP. No increase or decrease of a particular HLA genotype could be ascertained with the disease, although we detected an antigen frequency of 29.5% for the serologically ill-defined DR"X3" specificity. We identified and sequenced HLA-DRB1 and DRB3 genes from the DR"X3" haplotype. The DR"X3" DRB1 gene was found to be identical to DRB1*1201 (DR5[w12]). A unique observation is its unusual linkage with DRB3*0101 (DRw52a) or DRB3*0301 (DRw52c) instead of the usual linkage with DRB3*0201/2 (DRw52b). These associations are rare in whites and blacks.     

高效液相色谱法同时测定复方对乙酰氨基酚维生素C泡腾片中2组分含量

目的 :建立同时测定复方对乙酰氨基酚维生素C泡腾片中对乙酰氨基酚和维生素C含量的高效液相色谱法。方法 :色谱柱 :YWG -C18柱 (10 μm,2 5 0mm× 4 .6mm) ;流动相 :甲醇 乙腈 0 .0 5mol·L-1磷酸二氢铵 磷酸缓冲液 (5 0∶11∶2 5 0 ) ;流速 :1.0mL·min-1;检测波长 :2 5 4nm。结果 :对乙酰氨基酚线性范围为 8～ 16 0mg·L-1;维生素C线性范围为 5～ 10 0mg·L-1。对乙酰氨基酚回收率为 10 0 .4 % (RSD =2 .4 0 % ) ,维生素C回收率为 10 1.2 % (RSD =1.90 % )。结论 :应用本法同时测定对乙酰氨基酚和维生素C含量 ,具有简便、快速、准确、可靠的特点     

卡尼汀的生物学作用及在血液透析患者中的临床应用

卡尼汀是长链脂肪酸进入线粒体进行氧化所必需的一种物质，其左旋异构体具有生物活性。正常人可通过饮食摄入和肝、肾合成产生卡尼汀，但尿毒症血液透析患者由于肾脏内源性合成卡尼汀减少，血液透析过程中大量清除，大多存在时间依赖性的卡尼汀缺乏。通过静脉注射、口服、透析液补充外源性左旋卡尼汀有利于纠正脂代谢紊乱，减少促红细胞生成素用量，改善骨骼肌症状和营养状态，提高生活质量。     

国产重组人类促红细胞生成素预防早产儿贫血

目的　观察重组人类促红细胞生成素 (r Hu EPO,商品名宁红欣 )对早产儿贫血的预防作用。　方法　将来自四所医院的 5 1例胎龄小于 35周、体重小于 2 0 0 0 g的早产儿随机分为预防组(31例 )和对照组 (2 0例 )。预防组予 r Hu EPO2 5 0 IU/ (kg·次 ) ,静脉或皮下注射 ,隔日 1次 ,每周 3次 ,共 4周。观察两组早产儿血红蛋白 (Hb)、红细胞压积 (Hct)、网织红细胞 (Ret)、血清铁及促红细胞生成素 (EPO)的动态变化。　结果　两组早产儿生后 Hb、Hct均逐渐下降 ,但预防组下降明显小于对照组 ,经 t检验 ,两组之间差异有显著性 (P<0 .0 0 1)。对照组有 4例输血 ,而预防组无一例输血 ,经精确 χ2检验 ,差异有显著性 (P=0 .0 19)。预防组 1周末 Ret较对照组明显升高 ,差异有显著性 (P<0 .0 5 )。预防组 2周末血清铁低于对照组 ,4周末更甚 ,经比较差异有非常显著性 (P<0 .0 1)。预防组EPO水平较对照组明显上升 ,差异有非常显著性 (P<0 .0 1)。　结论　早产儿预防性应用 r Hu EPO可减轻 Hb、Hct、Ret的下降程度 ,不需要输血和输血次数减少 ,r Hu EPO预防早产儿贫血有一定效果。     

高原地区中毒型菌痢抢救休克、脑水肿51例体会

中毒型菌痢临床表现复杂 ,病情变化快 ,在整个抢救过程中应抓住主要环节 ,尽量诊断分型治疗。休克型以扩充血容量 ,纠正酸中毒基础上加用血管活性药物。脑水肿型以高渗脱水剂为主。混合型在使用扩血管药的基础上 ,采取补液、脱水的原则。     

颈总动脉切除术10例回顾性分析

目的 探讨颈总动脉切除术的适应症和术前准备的一般规律。方法 对我院自1986年～2003年17年问的10例颈总动脉切除术病例进行回顾性分析。其中年龄22～59岁，急诊手术4例，选择性颈动脉切除6例。结果 急诊手术中2例出现中枢神经系统并发症，选择性手术组中1例出现中枢神经系统并发症。除1例因脑转移癌死亡外，随访均健在。结论 行不重建血管的颈总动脉及分歧部切除术，高龄患者须严格掌握适应症，须无脑血管疾病史，术前须进行Matas试验，要有侧支循环建立的客观依据；对年轻患者(30岁以下)可适当放宽手术指征。     

Left hemihepatectomy in living donors with a thick middle hepatic vein draining the caudal half of the right liver

Donor safety is the first consideration in living related liver transplantation. Left hemihepatectomy including the middle hepatic vein is a reasonable donor procedure for obtaining a large graft for living related liver transplantation. This procedure, however, needs to be modified in donors with hepatic venous variation. While carrying out donor hepatectomy, we encountered two cases showing a variant form of hepatic venous drainage comprising a thick middle hepatic vein draining segment 6 of the liver. This variation made it necessary to preserve the middle hepatic vein in the donor liver remnant. Failure to recognize such a variant would result in congestion in the remaining right liver of the donor. To guarantee donor safety, evaluation of the drainage area of the corresponding hepatic vein is a matter of great importance in donor hepatectomy.     

Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.

PURPOSE: To assess the efficacy of neoadjuvant paclitaxel and carboplatin (TC) followed by concurrent cisplatin and radiotherapy (RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to monitor treatment response with plasma Epstein-Barr virus (EBV) DNA. PATIENTS AND METHODS: Thirty-one patients with International Union Against Cancer stages III and IV undifferentiated NPC had two cycles of paclitaxel (70 mg/m2 on days 1, 8, and 15) and carboplatin (area under the curve 6 mg/mL/min on day 1) on a 3-weekly cycle, followed by 6 to 8 weeks of cisplatin (40 mg/m2 weekly) and RT at 66 Gy in 2-Gy fractions. Plasma EBV DNA was measured serially using the real-time quantitative polymerase chain reaction method. Results All patients completed planned treatment. Response to neoadjuvant TC was as follows: 12 patients (39%) achieved partial response (PR) and 18 achieved (58%) complete response (CR) in regional nodes; five patients (16%) achieved PR and no patients achieved CR in nasopharynx. At 6 weeks after RT, one patient (3%) achieved PR and 30 patients (97%) achieved CR in regional nodes, and 31 patients (100%) achieved CR in nasopharynx; 29 patients (93%) had EBV DNA level of less than 500 copies/mL. Neoadjuvant TC was well tolerated, and the most common acute toxicity of cisplatin plus RT was grade 3 mucositis (55%). At median follow-up of 33.7 months (range, 7 to 39.3 months), six distant and three locoregional failures occurred. Plasma EBV DNA level increased significantly in eight of nine patients who experienced treatment failure but did not increase in those who did not. The 2-year overall and progression-free survival rates were 91.8% and 78.5%, respectively. CONCLUSION This strategy was feasible and resulted in excellent local tumor control. Serial plasma EBV DNA provides a noninvasive method of monitoring response in NPC.     

非小细胞肺癌中细胞周期蛋白D1与E的作用及相互关系

目的 :研究细胞周期蛋白D1与E在非小细胞肺癌 (NSCLC)发生、发展中的作用及相互关系。方法 :免疫组化方法检测 87例NSCLC肿瘤组织中细胞周期蛋白D1、E的表达及PCNA估计增殖指数 (PI) ,并将上述结果与临床病理及预后资料进行对比分析。结果 :87例NSCLC中细胞周期蛋白D1、E阳性率分别为 4 4 .8% (39/87)、4 8.3% (42 /87) ,细胞周期蛋白D1阳性组的PI值显著高于阴性组 (P〈0 .0 5 ) ,细胞周期蛋白E阳性组PI值与阴性组无显著差异 (P〉0 .0 5 ) ;细胞周期蛋白D1阳性组肿瘤直径、淋巴结转移率和生存率均与阴性组有显著差异(P〈0 .0 1、〈0 .0 5、〈0 .0 1) ,细胞周期蛋白E阳性组淋巴结转移率、临床分期和生存率均与阴性组有显著差异 (P〈0 .0 5、〈0 .0 5、〈0 .0 1) ;细胞周期蛋白D1阳性组中细胞周期蛋白E的阳性率显著高于其阴性组 (P〈0 .0 5 ) ;细胞周期蛋白D1与细胞周期蛋白E双阳性组的PI值、肿瘤直径、淋巴结转移率显著高于非双阳性组 (P值均〈0 .0 5 ) ,生存率显著低于非双阳性组 (P〈0 .0 1)。结论 :细胞周期蛋白D1、细胞周期蛋白E均参与NSCLC的发生、发展 ,并影响其预后 ,但两者在其中所起作用不同 :细胞周期蛋白D1是调节NSCLC增殖的主要因素 ,细胞周期蛋白E主要与NSCLC进展有关 ;细胞周期蛋白D1可促